Skip to main content

Cardio/Pulmonary

A new mechanism of action in SARD-ILD

Nerandomilast, an inhibitor of phosphodiesterase 4B, orally administered, is a new mechanism of action to treat lung fibrotic diseases. FIBRONEER-ILD, the Phase 3 RCT of Nerandomilast in patients with progressive pulmonary fibrosis, was 

Read Article
Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 https://t.co/jPAai9FLkb
Dr. John Cush @RheumNow( View Tweet )
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4
Dr. John Cush @RheumNow( View Tweet )
Psoriatic Arthritis at Risk for Interstitial Lung Disease A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD). https://t.co/2zuxF1PY3Q. https://t.co/Icck4qE76X
Dr. John Cush @RheumNow( View Tweet )
#CAR-T in active #scleroderma #diffuse open label @sclerodermaUM presented improvement in #nailfold #capillary patterns Suggesting #vascular recovery Hope is for lungs, skin and survival to improve but These are ▶️ Early days ?risk OP0338 #EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk
Janet Pope @Janetbirdope( View Tweet )
Is there an association btwn ⬆️ CRP & cardiovascular dysfunction in #axSpA? 🔹️245 pts 🔹️CRP recorded for past 5y 🔹️sustained high CRP in 40% 🔹️associated with ⬆️ cardiovascular risk factors, ⬇️endothelial function & subclin atheroslerosis POS0714 #EULAR2025 @RheumNow https://t.co/jAlj3sr95H
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Manifestations of relapsing polychondritis @Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them. ✅ Only 13% linked SLE control to CVD risk 🚫 0% picked correct BP/statin use in RA/AS/PsA Barriers? Time, knowledge, and local guideline gaps. POS0410-HPR @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n
Mrinalini Dey @DrMiniDey( View Tweet )
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Suppression of inflammation fire 🔥 in #axSpA may prevent subclinical atherosclerosis progression ❤️ 🔺️90 patients 🔺️74% achieved LDA at 12 mo 🔺️Carotid plaque progression was higher in non-LDA group POS1311 #EULAR2015 @RheumNow

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Will climate change impact rheumatological care? #EULAR2025 @rheumnow Especially larger cities are are affected more. Need to worry about comorbidities https://t.co/KhTyAssGeI
Bella Mehta @bella_mehta( View Tweet )
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk - Chikungunya - Dengue - Zika - West-Nile Virus @RheumNow #EULAR2025 https://t.co/HtHyADsOSX
Bella Mehta @bella_mehta( View Tweet )
#GameChanger Subset analysis of #CTD Pts with Progressive pulmonary fibrosis #PPF Ok background #nintedanib 1/3 ❎lung IS 2 doses #PDE4Bi #nerandomilast vs #PBO each dose ⬇️worsening #FVC vs PBO ⬇️lung events - hospital ⬇️death GI A/E #EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
Janet Pope @Janetbirdope( View Tweet )
KORAIL cohort: new RA-ILD progression model (inc. DLCO, ILD pattern/extent, anti-CCP, ± KL-6) stratified risk with high sensitivity & specificity. Adding KL-6 boosted AUC to 0.75. A step toward personalised care in RA-ILD. @RheumNow #EULAR2025 #OP0328 https://t.co/AHqNFw40gk
Mrinalini Dey @DrMiniDey( View Tweet )
Is #PDE5i protective in development of #SSc #ILD? Maybe 444 w ILD of >4000 #EUSTAR Pts over 1 to 2 yrs f/u #immunesuppressive use maybe or not 🤷‍♀️channeling bias Reduction in new #ILD in #scleroderma PDE5i ✅ Immunesuppression ? @RheumNow #EULAR2025 @eular_org #OP0334 https://t.co/6dtLfybkRV
Janet Pope @Janetbirdope( View Tweet )
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#guidelines everywhere @jeffsparks presents points of interest from #ACR #ILD #recommendations - a joint venture with American College of Chest Physicians While simultaneously the EULAR ILD recommendations are being unveiled! @RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9
Janet Pope @Janetbirdope( View Tweet )
Should we screen for #lung #cancer in #SSc high risk Pts? When >10 yrs? Greek cohort of SSc since 1995 Disease duration 12 yrs, smoking lung ca group ⬆️58% vs 29% ⬆️dcSSc ⬆️immunosuppression OR >4X lung ca if dcSSc, IS Less #DU #PO0940 @RheumNow @eular_org #EULAR2025 https://t.co/L2zEkP8pAc
Janet Pope @Janetbirdope( View Tweet )
Some RA-ILD is less of a worry, some is critical. How do we stratify? Great modelling work from Korea & @jeffsparks - model stratifying really well, even without KL-6. We need to do this more, so we can go really hard early when we need to. #EULAR2025 OP0329 @RheumNow https://t.co/i2djatO3F2
David Liew @drdavidliew( View Tweet )

Predictors and Outcomes in Systemic Sclerosis

EurekAlert!

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Read Article

EULAR 2025 – Day 2 Report

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few

Read Article

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic

Read Article
Ultrasound for ILD detection in RA 🫁 Sens 88.6 Spe 92.8 NPV 91.4 PPV 90.7 While if abnormal or high suspicion, HRCT should be the reference, I see this as an interesting tool in clinics for quick screening POS0180 #EULAR2025 @RheumNow https://t.co/pUy0ki7Y6S
Aurelie Najm @AurelieRheumo( View Tweet )
#HOT topic Lung 🫁 #ultrasound for #RA #ILD #LUS B lines vs HRCT Single site 🇫🇷 study V sensitive & specific 🤔needs standardization & comparison in other groups Abst#POS-180 #EULAR2025 @RheumNow @eular_org https://t.co/PwGE4rgk40
Janet Pope @Janetbirdope( View Tweet )
×